Stay informed with the latest news from the Philippines and around the world. Get updates on local and breaking news, explore odd and unique stories, read opinions and analyses, and view captivating news photos and videos.
Friday, June 10, 2022
FDA MedWatch - SnoreStop NasoSpray by Green Pharmaceuticals:
Recall - Due to Microbial Contamination
If your email program has trouble displaying this email, view as a webpage.
MedWatch - The FDA Safety Information and Adverse Event Reporting Program
TOPIC: SnoreStop NasoSpray by Green Pharmaceuticals: Recall - Due to Microbial Contamination
AUDIENCE: Consumer, Health Professional
ISSUE: Green Pharmaceuticals is recalling lot 2373/21222 of SnoreStop NasoSpray because FDA testing found product to contain microbial contamination identified as Providencia rettgeri.
This microorganism is rarely associated with human illness; however, in immunocompromised patients, the use of the recalled product could potentially result in severe or life-threatening adverse events such as bacteremia/sepsis, pneumonia, invasive fungal rhinosinusitis, or disseminated fungal infection. In non-immunocompromised patients, the use of the recalled product may result in infectious complications that are expected to be less severe and more readily responsive to treatment.
To date, Green Pharmaceuticals has not received any reports of adverse events related to this recalled lot.
For more information about this recall, click on the red button "Read Recall" below.
BACKGROUND: The product is used as a nasal spray to temporarily help stop or reduce symptoms of non-apneic snoring.
RECOMMENDATIONS:
Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.
Consumers and retailers that have product which is being recalled should stop using and return to place of purchase. Green Pharmaceuticals is arranging for return and replacement of all recalled products.
Consumers with questions regarding this recall can contact the company.
Health professionals and consumers are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration · 10903 New Hampshire Ave · Silver Spring, MD · 20993-0002 · 1-888-INFO-FDA
No comments:
Post a Comment